Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading

Abstract

Despite improvements in treatment and diagnostics over the last two decades, invasive aspergillosis (IA) remains a devastating fungal disease. The number of immunocompromised patients and hence vulnerable hosts increases, which is paralleled by the emergence of a rise in IA cases. Increased frequencies of azole-resistant strains are reported from six continents, presenting a new challenge for the therapeutic management. Treatment options for IA currently consist of three classes of antifungals (azoles, polyenes, echinocandins) with distinctive advantages and shortcomings. Especially in settings of difficult to treat IA, comprising drug tolerance/resistance, limiting drug-drug interactions, and/or severe underlying organ dysfunction, novel approaches are urgently needed. Promising new drugs for the treatment of IA are in late-stage clinical development, including olorofim (a dihydroorotate dehydrogenase inhibitor), fosmanogepix (a Gwt1 enzyme inhibitor), ibrexafungerp (a triterpenoid), opelconazole (an azole optimized for inhalation) and rezafungin (an echinocandin with long half-life time). Further, new insights in the pathophysiology of IA yielding immunotherapy as a potential add-on therapy. Current investigations show encouraging results, so far mostly in preclinical settings. In this review we discuss current treatment strategies, give an outlook on possible new pharmaceutical therapeutic options, and, lastly, provide an overview of the ongoing research in immunotherapy for IA.

Keywords: Immunotherapy; Invasive aspergillosis; Therapy.

Fig. 1

Therapy of invasive aspergillosis—current approach and outlook. LAmB = liposomal amphotericin-B; m.a. = mold active; CAR = chimeric antigen receptor; rIFN = recombinant infereron; PD-1 = programmed cell death protein 1. °In case of monotherapy, class need to be switched; Azole is an option in case of initial treatment with LAmB, insufficient plasma levels, or limiting drug–drug interactions/adverse events. *Beneficial results in mouse model of influenza and pseudo-COVID-associated pulmonary aspergillosis